focus -WSS

focus

author：entertainment 2025-10-01 04:13:27 - browse：3964

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The problem with charging patients to message their doctors

focus

WSS

Pumping milk in bathrooms at health conferences is common

High breast density mammograms need follow

High breast density mammograms need follow

RSV shot was 90% effective at preventing hospitalizations in kids

There's an unseen cost to disruptive road

The problem with charging patients to message their doctors

leisure time

focus

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

The drug industry has found itself all alone in Washington

In age of alternative facts, a scholarly course on calling out crap

Cardiologists urge adding sexual orientation, gender identity to health records

Trump demands the U.S. pay no more for drugs than other countries … again

Just how do doctors, lawmakers, and the public define abortion?

Malaria cases in Florida and Texas: Here’s what you need to know

NEJM study link tiny plastics in blood vessels to heart problems

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Head of FDA's diagnostics center, who led through Covid, retires

knowledge

The inclusion problem at the heart of rehabilitation research

Printout prescription drug information shouldn’t go digital

Mass General, Mayo Clinic look to monetize custom

Pumping milk in bathrooms at health conferences is common

The Readout: Amylyx, Alumis, and Lundbeck drug updates

CVS is on a mission to consolidate health care. Will it work?

hotspot

focus

knowledge

focus